bevacizumab,panitumumab
roche,amgen
['rectal', 'colorectal', 'bevacizumab', 'panitumumab']
among patients with ras wild-type metastatic colorectal cancer, adding panitumumab, vs bevacizumab, to standard first-line chemotherapy significantly improved overall survival in patients with left-sided tumors and in the overall population. #aacr23 
JAMA is an international peer-reviewed general medical journal published weekly online and in print, and a member of the @JAMANetwork family of journals.